News

Bahrain authorises "Sotrofimab" for emergency use

Bahrain authorises "Sotrofimab" for emergency use
02 Jun 2021

The Kingdom of Bahrain's National Health Regulatory Authority (NHRA) has approved "Sotrofimab" for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19.
 
The decision to add "Sotrofimab" to COVID-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK's clinical trials.
 
“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation.
 
Safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalisation for more than 24 hours and a reduction in the number fatalities by 85%, when administered at an early stage of treatment.